cyrilzakka/clinical-trials huggingface dataset:
Prevalence of Molar Incisor Hypomineralization Among Children Treated With Asthmatic Drugs Early in Their Lives

The aim of this study is to assess the prevalence of molar incisor hypo mineralization among children who have been treated with asthmatic drugs during the first three years of life.

The term Molar incisor hypo mineralization (MIH) was first introduced in 2001 as a developmental disorder of enamel characterized by hypo mineralization -of systemic origin - affecting the enamel of first permanent molars (PFM) ,frequently associated with affected permanent incisors.

The prevalence of MIH varies widely, ranging from 2.4 % to 40.2% in different populations. This wide variation may be due to differences in diagnostic criteria and methodologies used by the authors. Concerning the etiology of MIH it is mostly related to pre natal, perinatal, and post natal illness.

Asthma and asthmatic drugs have been proposed to be one of the etiological factors of MIH,Internationally, the mean prevalence of pediatric asthma is 10%.

Eligibility Criteria:
Inclusion Criteria:

1. Children from 8 to 12 years old with fully erupted first permanent molars and permanent incisors.
2. Children who were patients of the Pediatric Pulmonary Clinic and had used asthma drugs (oral and inhaled bronchodilators or corticosteroids) during their first three years of life.

Exclusion Criteria:

1. Children with any chronic disease
2. Children with unerupted or partially erupted first permanent molars.
3. Children using a fixed orthodontic appliance
4. Children having extensive carious lesions that might mask dental enamel defects.
Multiparametric Whole-Body MRI: a Game Changer in Metastatic Prostate Cancer

WB-MRI is a next-generation imaging technique standardized with the first version of MET-RADs-P guidelines.This narrative review aims to analyse the main scientific evidence available in the literature, explaining what WB MRI is and showing its decisive role in metastatic PC.

Prostate cancer ranks among the most prevalent tumours globally. While early detection reduces the likelihood of metastasis, managing advanced cases poses challenges in diagnosis and treatment. Current international guidelines support the concurrent use of 99Tc-Bone Scintigraphy and Contrast-Enhanced Chest and Abdomen CT for the staging of metastatic disease and response assessment. However, emerging evidence underscores the superiority of next-generation imaging techniques including PSMA-PET/CT and whole-body MRI (WB-MRI). This review explores the relevant scientific literature on the role of WB-MRI in metastatic prostate cancer. This multiparametric imaging technique, combining the high anatomical resolution of standard MRI sequences with functional sequences such as diffusion-weighted imaging (DWI) and bone marrow relative fat fraction (rFF%) has proved effective in comprehensive patient assessment, evaluating local disease, most of the nodal involvement, bone metastases and their complications, and detecting the increasing visceral metastases in prostate cancer. It does have the advantage of avoiding the injection of contrast medium/radionuclide administration, spares the patient the exposure to ionizing radiation, and lacks the confounder of FLARE described with nuclear medicine techniques. Up-to-date literature regarding the diagnostic capabilities of WB-MRI, though still limited compared to PSMA-PET/CT, strongly supports its widespread incorporation into standard clinical practice, alongside the latest nuclear medicine techniques.

Eligibility Criteria:
Inclusion Criteria: Literature extracted through the PubMed search engine, following PRISMA checklist, using the keywords:

* "Whole Body MRI"
* "Diffusion Weighted Imaging"
* "PET-CT and WB-MRI"
* "Metastatic Prostate Cancer"
* "Biochemical Recurrence in Metastatic Prostate Cancer"
* "DWIBS"
* "Multiparametric MRI"
* "response assessment in metastatic prostate cancer"
* "Dixon Method",
* "bone biopsy in metastatic prostate cancer",
* "bone metastases in prostate cancer",
* "MET-RADs".
* analysis from 1995 to April 2024.

Exclusion Criteria:

* duplicates
* repetitive,
* irrelevant,
* unrelated,
* out-of-date guidelines,
* case reports
Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions

Subjects are to be enrolled in this clinical study if they are 18 - 55 years old. Up to 120 subjects will be enrolled at multiple study centers. Subjects may receive up to 5 treatments for a wide array of dermatologic conditions in which electrocoagulation and hemostasis is a viable mechanism for means of improvement.


Eligibility Criteria:
Inclusion Criteria:

* A healthy, non-smoking male or female between the age of 18-55 years old.
* Fitzpatrick skin type I to VI.
* Understands and accepts obligation not to receive any other procedures on the treatment area through the length of the study.
* Understands and accepts the obligation and is logistically able to be present for all visits.
* Is willing to comply with all requirements of the study and sign the informed consent document.

Exclusion Criteria:

* Is pregnant or of childbearing potential and not using medically effective birth control, or has been pregnant in the last 3 months, currently breast feeding or planning a pregnancy during the study.
* The subject is currently enrolled in an investigational drug or device trial or has received an investigational drug or been treated with an investigational device within in the area to be treated 6 months prior to entering this study.
* The subject has physical problems such as cardiovascular disorders.
* The subject has a pacemaker.
* The subject had previous use of gold thread skin rejuvenation.
* The subject has skin infections.
* The subject has any of the following conditions:

  * Diabetes
  * Epilepsy
  * Acute disease
  * Dermatitis
* Subjects with electronic implants such as cardiac defibrillator. It may interfere with operation of electronic implants or damage the implants, causing risks.
* The subject has any condition or is in a situation which in the investigators opinion may put the subject at significant risk, may confound study results or may interfere significantly with the subject's participation.
The Effect and Mechanism of Self-compassion on Reducing Materialism

The current study provided an initial investigation of the effect of self-compassion on reducing materialism and explored the basic psychological needs and self-esteem as potential mechanisms. Two studies would be conducted. Study 1 explored the relationships among variables with cross-sectional data, to explore the relationship between self-compassion and materialism, and test the mediating role of basic psychological needs and self-esteem. Study 2 developed a new online self-help self-compassion intervention and conducted a randomized control trial (i.e., intervention group and waitlist group) to further explore the casual effect of self-compassion on materialism, with the mediating effect of basic psychological needs and self-esteem.

The inclusion criteria were as follows: (1) consented to accept randomization, finish the intervention and fill out questionnaires and (2) had no current or previous mental disorder diagnosis.

The Chinese Version of Self-compassion Scale (SCS-C; Chen et al., 2011) was used to measure the self-compassion level of participants. The Rosenberg Self-Esteem Scale (RSES; Rosenberg, 1965) was used to measure self-esteem using 10 items. The Balanced Measure of Psychological Needs Scale (BMPN; Sheldon \& Hilpert, 2012) was used to measure basic psychological needs. The Material Tendencies Scale (MTS; Zhang \& Xiao, 2019) was used to measure materialism.

Eligibility Criteria:
Inclusion Criteria:

1. consented to accept randomization, finish the intervention and fill out questionnaires and
2. had no current or previous mental disorder diagnosis.

Exclusion Criteria:

1. did not accept randomization, can not finish the intervention and fill out questionnaires
2. had current or previous mental disorder diagnosis.
A Study Assessing the Tolerable Upper Intake Level and Safety of Sugars From Fiber

The purpose of this study is to determine the upper tolerable limit of Sugars from Fiber


Eligibility Criteria:
Inclusion Criteria:

* Give written informed consent;
* Be between 18 and 60 years of age inclusive;
* Have a body mass index \<30 Kg/m2;
* Be in general good health, as determined by the investigator;
* Have a habitual dietary intake of ≥13g fibre/day;
* Self-reported consumption of a generally 'healthy diet'.

Exclusion Criteria:

* Females who are pregnant, lactating or wish to become pregnant during the study;
* Participant has self-reported low-energy diet or other extreme dietary habits;
* Have experienced recurrent loose stool within the past 4 weeks;
* Recent gastroenteritis or food borne illness such as confirmed food poisoning within the past 4 weeks;
* Have taken a medication or dietary supplement that may influence GI activity within the 2-weeks prior to screening;
* Have a history of abdominal surgery (excluding appendectomy);
* Have taken anaesthesia within the past 4 weeks;
* Have a known or suspected food allergy or intolerance to any of the investigational product ingredients;
* Have taken antibiotics within the past 12-weeks;
* Have a recent history of drug and/or alcohol abuse at the time of enrolment;
* Are a smoker (defined as \>5 cigarettes/week);
* Have made any major dietary change in the past 3 months;
* Have planned major changes in lifestyle (i.e. diet, dieting, exercise level, travelling) during the duration of the study;
* Have an active gastrointestinal disorder or previous gastrointestinal surgery;
* Have irritable bowel syndrome, diagnosed or undiagnosed and treated with chronic medications;
* Have a gastrointestinal disease i.e., chronic diarrhoea, Crohn's disease, ulcerative colitis, diverticulosis, stomach or duodenal ulcers, or with a history of such diseases;
* Have a metabolic or endocrine disorder such as diabetes, thyroidism, or other metabolic disorder;
* Have a severe chronic disease i.e. cancer, renal failure, hepatitis, HIV, cirrhosis etc., or with a history of such diseases;
* Are severely immunocompromised (HIV positive, transplant patient, on antirejection medications, on a systemic steroid for \>30 days, or chemotherapy or radiotherapy within the last year);
* Have a personal history of anorexia nervosa, bulimia, or significant eating disorders;
* Experiences alarm features such as unintentional weight loss, rectal bleeding, recent change in bowel habit (\<3 months) or abdominal pain;
* Participants who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial;
* Participant is currently receiving treatment involving experimental drugs. If the participant has been in a recent experimental trial, these must have been completed not less than 30 days prior to this study.
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

The purpose of this study is to collect DNA samples from patients undergoing routine care at the University of Chicago. These samples will be tested for differences in genes that may suggest greater risk of side effects or chance of increased benefit from certain medications. The results will be made available to the patient's treating physician and the researchers will track whether or not this information is used in routine health care.


Eligibility Criteria:
Inclusion Criteria:

* Receiving ongoing, out-patient care at the University of Chicago Medical Center under the routine care of a physician participating in this trial
* Life expectancy of at least 3 years
* Must be 18 years or older
* Must be taking at least 1 (but not more than 6) prescription medications at the time of enrollment OR be 65 years or older OR be reasonably expected to require the use of a prescription medication within the next 5 years
* Patients with certain diseases, or likely to receive or be receiving certain drugs, will be targeted particularly for enrollment in order to enrich the study for patients likely to have pharmacogenetically relevant interactions, including, but not limited to:

  * Patients requiring specialized cardiology care
  * Patients with inflammatory bowel diseases
  * Patients with systemic autoimmune or inflammatory diseases
  * Patients requiring long-term oral anticoagulation
  * Patients with hepatitis C
  * Patients with non-metastatic cancer

Exclusion Criteria:

* Patients with acute or chronic disease which could be reasonably expected to result in the patient's death within the next 3 years.
* Patients who have undergone, or are being actively considered for, liver or kidney transplantation.
* Inability to understand and give informed consent to participate.
ImmuNe ParameTERs to Predict Immunotherapy REsponse and Toxicity (INTERPRET)

This is a prospective observational study that will collect blood samples at 1-10 timepoints related to initiation of immunotherapy. The study may collect samples before the start of immunotherapy and/or at clinically significant timepoints during immunotherapy treatment.

The long-term goal of this research is to identify immunologic and other blood-borne markers of immunotherapy efficacy and toxicity. The objective of this proposal is to identify associations between immunologic parameters and other blood-borne markers with treatment response, irAE development, or relevant biomarkers of both outcomes.

Eligibility Criteria:
Inclusion Criteria:

1. ≥ 18 years old at the time of informed consent.
2. Have a diagnosis of cancer and initiating therapy with single agent or combination therapy that includes an immunotherapy (see Appendix 16.1 for list of immunotherapy classes).
3. Ability to provide written informed consent and HIPAA authorization.

Exclusion Criteria:

1. Not meeting any of the previously described inclusion criteria.
The Peanut Ball Use on Labor

The purpose of this study was to evaluate the effect of using peanut balls during labor on labor memory, labor satisfaction, labor length, and neonatal APGAR scores.

The purpose of this study was to evaluate the effect of using peanut balls during labor on labor memory, labor satisfaction, labor length, and neonatal APGAR scores.

This randomized, controlled, single-blind trial was conducted in 156 primiparous pregnant women (peanut ball group n=78, control group n=78) who delivered between March 2024 and October 2024. Pregnant women in the peanut ball group were instructed to perform movements with the peanut ball after cervical dilation reached 4 cm. The control group received only standard intrapartum midwifery care. Data were collected by personal information form, labor and postpartum follow-up form (APGAR score, etc.), Birth Memory and Recall Scale 4 hours after delivery, and Birth Satisfaction Scales.

Eligibility Criteria:
Inclusion Criteria:

Pregnant women were included if they had indications for vaginal delivery,

* Were primiparous,
* Had cervical dilation of 3 cm or more,
* Had term pregnancy (38 to 42 weeks of gestation),
* Had a single,
* Healthy,
* Vertex-positioned fetus,
* Had no complications that could cause dystocia during labor (contraction anomalies, birth object, dystocia related to the birth canal, dystocia related to the mother's psyche, dystocia related to the mother's psychology),
* Did not use analgesia and anesthesia during the first stage of labor,
* I did not have any physical disability to take the positions to be used in the study,
* Did not have any communication problems,
* Had language skills sufficient to speak and understand Turkish.

Exclusion Criteria:

* Pregnant women were excluded if they had abnormal changes in fetal heart rate during labor (fetal distress, etc.),
* Had an unexpected pregnancy or fetal complication,
* Had a high-risk pregnancy,
* Were taking magnesium sulfate,
* Had symptoms of intrauterine infection,
* Had previously attended antenatal classes,
* Or reported having been educated about birthing balls.
Analysis of Surface EKG Signals to Identify Myocardial Dysfunction in Patients at Risk for Coronary Artery Disease

1. The MyoVista device is capable of detecting surface electrocardiogram signals and sensitive in detecting coronary artery disease compared to traditional computed tomography angiography (CTA)
2. Electrophysiological signals at the cellular level of myocardium are related to specific patterns on the MyoVista device
3. Changes in MyoVista device output and can indicative of future CAD outcomes and need for revascularization

Background Myocardial ischemia is caused by myocardial oxygen supply and demand mismatch. Despite that coronary artery disease (CAD) is the major cause of myocardial ischemia, the symptoms may occur even in the absence of significant CAD. One of the mechanisms suggested for myocardial ischemia in these patients is microvascular ischemia (i.e. mismatch in microscopic vessels), affecting the myocardium (i.e. heart muscle) at the cellular level.

A novel electrocardiographic recording method, the iECG is capable of capturing and amplifying signals from the cellular level that are much lower biologic signals than those processed by a traditional electrocardiogram (ECG). These recordings focus on early detection of myocardial abnormalities by non-linear analysis of electrical activity and physiological phenomenon. This novel assessment might be capable of detecting subclinical myocardial dysfunction in a variety of heart diseases.

Specific Aims

Aim#1: Study the feasibility of detection of CAD using iECG compared to computed tomographic coronary angiography (CTA).

Aim#2: Study the association between patterns of iECG and myocardial dysfunction in patients without CAD compared to echocardiography.

Aim#3: Study the effect of changes in iECG output on future outcomes of CAD and need for revascularization.

Eligibility Criteria:
Inclusion Criteria:

* Sinus rhythms
* Age\>18 years
* Both genders

Exclusion Criteria:

* Acute coronary syndromes(ACS)
* Contraindications to the administration of iodinated contrast
* Pregnancy
* Coronary artery bypass surgery (CABG)
* History of cardiac valvular replacement
* Implanted cardiac pacemaker
* Chest deformities
* Unwilling or unable to provide informed consent for study participation
* Enrolled in another clinical study
Effects of Walking Apnea at High Lung Volume on Hypoalgesia, Cardiovascular Function and Respiratory Function

The aim of this randomized controlled study is to explore the hypoalgesic response of a 6 minutes of intermittent walking apneas training session at high lung volume in healthy subjects; also, as secondary objectives, to analyze the cardiovascular and respiratory response produced during the intervention.


Eligibility Criteria:
Inclusion Criteria:

- Asymptomatic subjects aged between 18 and 64 years.

Exclusion Criteria:

* Cardiovascular, respiratory, metabolic, neurological or osteomuscular signs or pathologies.
* History of epilepsy.
* Pregnant
* Pharmacological treatment.
* Participants who present any type of pain on the day of the measurements or who have frequently suffered pain during the previous 4 weeks.
Effects of Lifestyle Modification on Metabolic Parameters in Type 2 Diabetic Patients

The study is a randomized controlled study comparing the metabolic effect of a 3 month intensive lifestyle modification intervention in Korean type 2 diabetic patients.


Eligibility Criteria:
Inclusion Criteria:

* age 25 or older,
* type 2 diabetes mellitus,
* HbA1c 6.5-10% BMI 23 or higher.

Exclusion Criteria:

* type 1 diabetes,
* recent (within 3 months) cardiovascular event,
* severe hepatic or renal dysfunction,
* insulin use,
* glucocorticoid use.
Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin

RATIONALE: Drugs used in chemotherapy, such as methotrexate, vinblastine, doxorubicin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Evaluating blood or tissue samples from patients with cancer may help doctors learn more about changes that occur in DNA, identify biomarkers related to cancer, and predict how well patients will respond to combination chemotherapy.

PURPOSE: This phase II trial is studying gene expression profiling to see how well it works in predicting response to treatment in patients with invasive bladder cancer receiving methotrexate, vinblastine, doxorubicin, and cisplatin.

OBJECTIVES:

Primary

* Analyze the correlation between gene expression profile and the effect of chemotherapy and detect the significant cluster of genes useful to predict chemosensitivity.
* Confirm the reduction in original tumor size in patients with invasive bladder cancer treated with methotrexate, vinblastine, doxorubicin hydrochloride, and cisplatin.

Secondary

* Determine the safety of this regimen in these patients.
* Determine the overall survival rate in patients treated with this regimen.
* Assess the reduction in size of metastatic lesions in patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive methotrexate on days 1, 15, and 22, vinblastine on days 2, 15, and 22, doxorubicin hydrochloride and cisplatin on day 2. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.

Patient samples will be collected for gene expression profiling.

After completion of study treatment, patients are followed for 3 years.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Diagnosis of invasive bladder cancer
* Must be confirmed by chest and abdominal CT scan OR pelvic MRI scan and transurethral biopsy (with definitive muscle invasion \> T2) within 4 weeks prior to registration

PATIENT CHARACTERISTICS:

* ECOG performance status 0-1
* WBC ≥ 3,000/mm\^3
* Neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Total bilirubin ≤ 1.5 mg/dL
* Serum creatinine ≤ 1.5 mg/dL
* AST and ALT ≤ 2.5 x upper limit of normal
* Not pregnant
* No liver cirrhosis
* No ischemic cardiovascular disease or arrhythmia for which treatment is necessary
* No cardiac infarction within the past 6 months
* No interstitial pneumonia, pulmonary fibrosis, or any other diseases by which oxygen inhalation therapy is needed
* No active cancerous lesion other than upper urinary tract tumor
* No high fever or any other infectious symptom
* No uncontrolled hypertension or diabetes mellitus

PRIOR CONCURRENT THERAPY:

* No prior systemic chemotherapy